Format

Send to

Choose Destination
Eur Urol. 2019 Sep 26. pii: S0302-2838(19)30731-6. doi: 10.1016/j.eururo.2019.09.011. [Epub ahead of print]

Reply to Xuefeng Liu's Letter to the Editor, re: Kimmo Kettunen, Peter J. Boström, Tarja Lamminen, et al. Personalized Drug Sensitivity Screening for Bladder Cancer Using Conditionally Reprogrammed Patient-derived Cells. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.06.016: Can Patient-derived Cancer Models Change the Costliest Cancer Type?

Author information

1
Institute of Biomedicine, University of Turku, and Department of Pathology, Turku University Hospital, Turku, Finland.
2
Department of Urology, Turku University Hospital and University of Turku, Turku, Finland.
3
Institute of Biomedicine, University of Turku, and Department of Pathology, Turku University Hospital, Turku, Finland. Electronic address: pekka.taimen@utu.fi.

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center